Last $16.48 USD
Change Today -0.12 / -0.72%
Volume 27.2K
OCUL On Other Exchanges
As of 8:10 PM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

ocular therapeutix inc (OCUL) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/14 - $16.97
52 Week Low
07/31/14 - $11.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ocular therapeutix inc (OCUL) Related Businessweek News

No Related Businessweek News Found

ocular therapeutix inc (OCUL) Details

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology for treating eye diseases and conditions. The company offers ReSure Sealant, a synthetic ocular sealant in sealing clear corneal incisions following cataract surgery. Its products also include Dexamethasone Punctum Plug, a drug-eluting punctum plug; Travoprost Punctum Plug or the treatment of glaucoma and ocular hypertension; Moxifloxacin Punctum Plug for the treatment of bacterial conjunctivitis; and posterior segment injections. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

54 Employees
Last Reported Date: 07/25/14
Founded in 2006

ocular therapeutix inc (OCUL) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $254.9K
Chief Operating Officer
Total Annual Compensation: $362.5K
Executive Vice President of Clinical, Regulat...
Total Annual Compensation: $321.5K
Compensation as of Fiscal Year 2013.

ocular therapeutix inc (OCUL) Key Developments

Ocular Therapeutix, Inc. Announces Resignation of Alan Crane from Board of Directors, Effective July 30, 2014

As anticipated and as disclosed in the prospectus related to the initial public offering of shares of common stock by Ocular Therapeutix, Inc., Mr. Alan Crane resigned from the company's board of directors effective as of July 30, 2014 immediately prior to the closing of the IPO. Mr. Crane's resignation was not related to any disagreements with the company on any matters relating to the company's operations, policies or practices. As also disclosed in the prospectus related to the IPO, Mr. Crane's resignation was preceded by the appointment and election of Mr. Bruce Peacock to the company's board of directors in July 2014 prior to the IPO.

Ocular Therapeutix, Inc.(NasdaqGM:OCUL) added to NASDAQ Composite Index

Ocular Therapeutix, Inc. will be added to the NASDAQ Composite Index.

Ocular Therapeutix Seeks Acquisitions

Ocular Therapeutix, Inc. has filed an IPO in the amount of $86.25 million. Ocular Therapeutix will use the net proceeds from this offering to fund the clinical development of most advanced product candidates, OTX-DP and OTX-TP, and for working capital and other general corporate purposes, including expansion of our manufacturing capacity, sales and marketing activities, development of preclinical product candidates and pursuit of other research and development efforts.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCUL:US $16.48 USD -0.12

OCUL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCUL.
View Industry Companies

Industry Analysis


Industry Average

Valuation OCUL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9,406.6x
Price/Book 23.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12,560.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULAR THERAPEUTIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at